Market Research Report
Seasonal Influenza: Competitive Landscape to 2026
|Published by||GlobalData||Product code||753099|
|Published||Content info||49 Pages
Delivery time: 1-2 business days
|Seasonal Influenza: Competitive Landscape to 2026|
|Published: November 8, 2018||Content info: 49 Pages||
Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses designated as influenza types A, B, and C. The influenza A H1N1 and H3N2, and influenza B strains are those responsible for seasonal influenza infections. The symptoms of influenza are similar to those of the common cold, though they are usually more severe, have a sudden onset, last for one to two weeks, and are normally self-limiting without medical treatment. The very young, elderly, and patients with chronic illness such as diabetes, asthma, or cardiovascular disease are most at risk of complications due to influenza.
This report provides an assessment of the pipeline, clinical, and commercial landscape of seasonal influenza. Overall, GlobalData expects new drug approvals to drive a shift in the treatment and prophylaxis of seasonal influenza over the next decade (2016-2026).
This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -